Abstract

LivaNova PLC will release quarterly results on August 05, 2026 Pre-Market; consensus points to revenue of 380.76 million US dollars (+14.59% year over year), adjusted EPS of 1.10 (+28.54% year over year), and EBIT of 80.21 million (+17.88% year over year), with investor attention centered on neuromodulation progress and margin resilience.

Market Forecast

Consensus for the upcoming quarter implies revenue of 380.76 million US dollars, adjusted EPS of 1.10, and EBIT of 80.21 million, translating to 14.59%, 28.54%, and 17.88% year-over-year growth, respectively; explicit forecasts for gross margin or net profit margin have not been provided. The setup suggests operating leverage as the key swing factor for EPS against a high-60s gross margin baseline from last quarter and a mid-single-digit net margin base.

The company’s revenue mix remains anchored by its cardiopulmonary portfolio and neuromodulation franchise; together, these businesses set the tone for top-line momentum and margin structure this quarter. Neuromodulation stands out as the near-term growth engine: it generated 151.79 million US dollars last quarter, and recent study readouts and product advancements indicate potential growth at or above the corporate average year over year, although segment-specific YoY figures were not disclosed.

Last Quarter Review

In the preceding quarter, LivaNova PLC delivered revenue of 362.30 million US dollars (+14.33% year over year), a gross profit margin of 67.59%, GAAP net profit attributable to shareholders of 22.29 million US dollars, a net profit margin of 6.15%, and adjusted EPS of 0.98 (+11.36% year over year). Adjusted EPS and revenue both came in ahead of expectations, indicating solid execution into the start of the fiscal year. Cardiopulmonary contributed 208.66 million US dollars and neuromodulation 151.79 million US dollars, supporting the company’s 14.33% year-over-year top-line growth; GAAP net profit was down 27.87% quarter over quarter, reflecting quarter-on-quarter volatility and mix.

Current Quarter Outlook

Cardiopulmonary portfolio

The cardiopulmonary portfolio remains the largest revenue contributor, with 208.66 million US dollars recorded last quarter, and will be central to sustaining mid-teens growth this quarter. The baseline gross margin of 67.59% underscores favorable pricing and mix for the group’s disposables and capital-related offerings, though quarter-to-quarter variability often tracks product mix, geographic mix, and manufacturing absorption. Investors will look for continued unit trends that align with the consensus revenue forecast of 380.76 million US dollars, as even modest outperformance here can meaningfully influence consolidated gross margin and EBIT.

Mix within cardiopulmonary matters for profitability: recurring disposables generally support steadier margin dynamics than large-equipment placements, and an improved conversion of capital to disposables can bolster the gross margin trajectory. FX exposure and procurement timing can add noise to quarter-to-quarter comparisons, but the prior quarter’s high-60s gross margin provides a helpful starting point for modeling this segment’s contribution. With EBIT forecast to rise 17.88% year over year to 80.21 million US dollars, the cardiopulmonary contribution to fixed-cost absorption and volume leverage will be under scrutiny as a determinant of whether EPS lands at or above the 1.10 consensus.

Neuromodulation and sleep-related initiatives

Neuromodulation generated 151.79 million US dollars last quarter and appears to be the most promising growth vector into this print, supported by recent updates in sleep-related therapies. Newly shared data indicate the company’s PolySync programming algorithm achieved an 84.5% cumulative response rate in moderate-to-severe obstructive sleep apnea patients within its Osprey study framework, a result that, while primarily clinical in nature, can shape investor expectations for medium-term adoption and revenue scalability. Management commentary and external previews this cycle have highlighted neuromodulation as a focal point for incremental growth and potential mix support to margins, even if formal quarter-specific margin guidance is not provided.

In the near term, neuromodulation performance will hinge on procedure flow, referral patterns, and the cadence of therapy optimization initiatives. The positive study update has already featured in market discussions and buttresses a constructive stance on the segment’s trajectory relative to the company-wide growth profile of 14.59% year over year. From a P&L standpoint, an expanding neuromodulation mix can offer a constructive push-pull on gross margin, depending on product and geography, and can support the consensus-adjusted EPS path of 1.10 if execution remains consistent.

Margins, operating leverage, and what could move the stock

Gross margin and operating leverage are likely to be the most influential financial variables for the stock reaction. Starting from a prior quarter gross margin of 67.59%, the market will gauge whether mix, procurement, and volume dynamics can hold or expand that level against the consensus revenue outcome of 380.76 million US dollars. A modest improvement in gross margin, coupled with disciplined operating expenses, would support the 17.88% year-over-year EBIT growth forecast to 80.21 million US dollars and underpin the 28.54% adjusted EPS growth to 1.10.

Net profitability is also a watch item after a 6.15% net margin last quarter and a 27.87% quarter-on-quarter decline in GAAP net profit attributable to shareholders. While that sequential decline does not necessarily dictate a trend, it raises the bar for achieving a cleaner conversion from EBIT to net income this quarter, particularly if non-operating items or tax rates move adversely. Investors will be attentive to whether the company can translate projected EBIT growth into proportionate improvements in net margin, which would help frame the sustainability of double-digit EPS growth.

Cash deployment priorities can influence valuation as well, even if they have limited near-term EPS impact. Clarity on reinvestment behind neuromodulation programs, manufacturing efficiencies, and commercial initiatives can help investors contextualize any change in operating expense growth relative to revenue. If management can demonstrate that incremental opex is tightly linked to high-return programs and that fixed costs are leveraged by volume, the 1.10 adjusted EPS mark may prove a mid-point rather than a ceiling.

Revenue quality and beat/raise dynamics

Given the prior quarter’s revenue and EPS beats versus estimates, the market will look for signs the company can execute a beat/raise pattern. The consensus implies a 14.59% year-over-year revenue increase to 380.76 million US dollars; upside of even one full point, coupled with stable gross margin, could drive a positive EPS surprise. Conversely, if mix or input costs pressure gross margin, the reported EPS could track in-line even if revenue meets consensus.

The composition of revenue is important for durability. A higher share from recurring disposables and therapy utilization would typically support steadier gross margin and predictability, whereas a heavier tilt toward capital placements can create lumpiness but also set up future consumables growth. Monitoring commentary around order patterns, backlog conversion, and utilization rates will be essential to assess how sustainable any acceleration in top-line growth might be into the second half.

Operating expenses, R&D cadence, and EBIT flow-through

The EBIT forecast of 80.21 million US dollars (+17.88% year over year) implies meaningful flow-through from revenue to operating profit. Achieving this will require careful management of selling, general, and administrative costs relative to revenue as well as disciplined R&D pacing. With neuromodulation and sleep-related initiatives remaining in focus, investors will want assurance that incremental R&D spend is yielding tangible clinical and commercial milestones that enhance the revenue slope.

Operating expense efficiency will remain a differentiator in translating gross profit into adjusted EPS. The company’s earlier beat on adjusted EPS (0.98 vs. a 0.897 estimate) suggests cost control contributed alongside revenue upside; the question now is whether that efficiency persists at a higher revenue base. A clean EBIT progression without outsized one-time items would help investors attribute EPS performance to core operations rather than transitory factors.

From EBIT to adjusted EPS and net income

Bridging from 80.21 million US dollars in forecast EBIT to 1.10 in adjusted EPS calls for attention to interest expense, tax rate, and share count. The company’s net margin of 6.15% last quarter provides a reality check on how EBIT growth translates to after-tax earnings, and whether non-operating items could become a swing factor this quarter. A benign tax and interest backdrop would improve the odds of delivering on the 28.54% adjusted EPS growth embedded in consensus.

Consistency across these elements often determines the direction of post-earnings revisions. Strong revenue and gross margin without commensurate net income flow-through may limit valuation upside, while a clean conversion from EBIT to adjusted EPS can build confidence in sustained double-digit growth. For investors, clarity on these below-the-line items can be as important as the top-line print.

What to watch in the print and commentary

- Revenue vs. the 380.76 million US dollars consensus, and color on intra-quarter order patterns. - Gross margin progression vs. last quarter’s 67.59%, with mix and procurement commentary. - Segment color: neuromodulation momentum following recent clinical updates, and cardiopulmonary volume trends. - Operating expense trajectory and implications for achieving 80.21 million US dollars EBIT. - Conversion from EBIT to adjusted EPS and signals on net margin relative to the 6.15% base.

Analyst Opinions

Across the views collected for the period, opinions skew bullish, with a 100% to 0% ratio of bullish to bearish calls. A notable example is Piper Sandler, where analyst Adam Maeder maintained a Buy rating and set an 85.00 US dollars price target in July, framing expectations around continued execution in core franchises and upside from neuromodulation-related catalysts. The prevailing stance emphasizes that the forecasted revenue of 380.76 million US dollars (+14.59% year over year), adjusted EPS of 1.10 (+28.54% year over year), and EBIT of 80.21 million US dollars (+17.88% year over year) are attainable, with a potential for upside if gross margin holds near the prior quarter’s 67.59% and operating expenses remain controlled.

Bullish commentary also highlights the recent clinical progress in sleep-related therapies, including the 84.5% cumulative response rate achieved by the PolySync programming algorithm in the Osprey study context, as an indicator of medium-term growth optionality within the neuromodulation franchise. This narrative dovetails with a focus on volume leverage and pricing/mix discipline to support EBIT growth and the 28.54% adjusted EPS expansion implied by consensus. In short, the majority view anticipates delivery consistent with, or slightly ahead of, consensus if margins stay resilient and neuromodulation maintains its current trajectory, with any incremental clarity on program milestones likely to reinforce a constructive outlook.